• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease.

作者信息

Basheer Maamon, Naffaa Mohamed, Assy Nimer

机构信息

Internal Medicine Department, Galilee Medical Center, Nahariya, Israel.

Rheumatology Unit, Galilee Medical Center, Nahariya, Israel.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):398-400. doi: 10.3350/cmh.2023.0045. Epub 2023 Feb 13.

DOI:10.3350/cmh.2023.0045
PMID:36775835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121291/
Abstract
摘要

相似文献

1
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中肝纤维化的非侵入性生物标志物
Clin Mol Hepatol. 2023 Apr;29(2):398-400. doi: 10.3350/cmh.2023.0045. Epub 2023 Feb 13.
2
Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.采用非侵入性方法准确诊断非酒精性脂肪性肝病相关肝纤维化：前进之评论
J Hepatol. 2020 Aug;73(2):465-466. doi: 10.1016/j.jhep.2020.03.020. Epub 2020 May 13.
3
Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者中无创性纤维化模型预测轻度至中度纤维化的性能。
Liver Int. 2016 Apr;36(4):572-9. doi: 10.1111/liv.13054. Epub 2016 Jan 24.
4
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.非酒精性脂肪性肝病中的肝纤维化——具有预后意义的诊断挑战
World J Gastroenterol. 2015 Oct 21;21(39):11077-87. doi: 10.3748/wjg.v21.i39.11077.
5
Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.减重手术期间的常规肝活检：循证分析
Obes Surg. 2016 Jan;26(1):177-81. doi: 10.1007/s11695-015-1916-z.
6
Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).非侵入性纤维化评分系统可预测非酒精性脂肪性肝病（NAFLD）患者未来的代谢并发症及总体死亡率。
Scand J Gastroenterol. 2019 Mar;54(3):328-334. doi: 10.1080/00365521.2019.1583366. Epub 2019 Mar 23.
7
Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.致编辑的信：使用机器学习模型诊断非酒精性脂肪性肝病中的纤维化和肝硬化
Hepatology. 2023 May 1;77(5):E103-E104. doi: 10.1097/HEP.0000000000000209. Epub 2023 Jan 3.
8
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.诊断非酒精性脂肪性肝病/非酒精性脂肪性肝炎：非侵入性检查足矣。
Liver Int. 2018 Feb;38 Suppl 1:67-70. doi: 10.1111/liv.13658.
9
The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.γ-谷氨酰转肽酶与血小板比值用于慢性乙型肝炎和非酒精性脂肪性肝病患者肝纤维化的无创评估
Oncotarget. 2017 Apr 25;8(17):28641-28649. doi: 10.18632/oncotarget.16162.
10
Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease.非酒精性脂肪性肝病的无创性肝纤维化检测。
Rev Esp Enferm Dig. 2022 Apr;114(4):191-194. doi: 10.17235/reed.2022.8718/2022.

引用本文的文献

1
The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver-A Secondary Analysis of the Pro-Demet Randomized Clinical Trial.抑郁症、益生菌、饮食、免疫代谢健康、肠道与肝脏之间的相互作用——Pro-Demet随机临床试验的二次分析
Nutrients. 2024 Nov 24;16(23):4024. doi: 10.3390/nu16234024.
2
New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?肝纤维化中的新生物标志物：在流沙中穿行？
J Pers Med. 2024 Jul 29;14(8):798. doi: 10.3390/jpm14080798.

本文引用的文献

1
The Baveno VII concept of cirrhosis recompensation.巴韦诺VII期肝硬化代偿概念
Dig Liver Dis. 2023 Apr;55(4):431-441. doi: 10.1016/j.dld.2022.12.014. Epub 2023 Jan 14.
2
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future.非酒精性脂肪性肝病肝纤维化的无创性血清标志物：现状与展望。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S157-S170. doi: 10.3350/cmh.2022.0348. Epub 2022 Nov 22.
3
Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study.非酒精性脂肪性肝病患者的患者报告结局受损：一项基于登记的研究。
Aliment Pharmacol Ther. 2023 Jan;57(2):215-223. doi: 10.1111/apt.17301. Epub 2022 Nov 11.
4
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.MEFIB、MAST 和 FAST 检测非酒精性脂肪性肝病患者 2 期及以上纤维化的头对头比较。
J Hepatol. 2022 Dec;77(6):1482-1490. doi: 10.1016/j.jhep.2022.07.020. Epub 2022 Aug 13.
5
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis.用于自身免疫性肝炎诊断和管理的非侵入性生物标志物。
Hepatology. 2022 Dec;76(6):1862-1879. doi: 10.1002/hep.32591. Epub 2022 Jun 8.
6
Impact of non-invasive biomarkers on hepatology practice: Past, present and future.非侵入性生物标志物对肝脏病学实践的影响：过去、现在和未来。
J Hepatol. 2022 Jun;76(6):1362-1378. doi: 10.1016/j.jhep.2022.03.026.
7
Breakthroughs in therapies for NASH and remaining challenges.NASH 治疗方面的突破和尚存的挑战。
J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.
8
Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study.用于检测全因性晚期肝纤维化的集成机器学习框架的开发与验证：一项回顾性队列研究
Lancet Digit Health. 2022 Mar;4(3):e188-e199. doi: 10.1016/S2589-7500(21)00270-3.
9
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.磁共振弹性成像（MRE）联合 FIB-4（MEFIB）指数在检测 NASH 相关纤维化药物治疗候选者中的应用。
Gut. 2021 Oct;70(10):1946-1953. doi: 10.1136/gutjnl-2020-322976. Epub 2020 Nov 19.
10
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.一种基于血液的生物标志物panel（NIS4），用于非酒精性脂肪性肝炎和肝纤维化的非侵入性诊断：前瞻性推导和全球验证研究。
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):970-985. doi: 10.1016/S2468-1253(20)30252-1. Epub 2020 Aug 5.